Dexcom Stock News

naphtalina/iStock via Getty Images Following a three-day selloff, DexCom (DXCM +2.9%) shares are trading higher after Wells Fargo upgraded the maker of continuous glucose monitoring

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

Kevin Sayer, the chief executive officer of Dexcom, appeared on Monday's episode of "Mad Money," discussing efforts to increase awareness of its continuous glucose monitoring devices, including its ne

DexCom <> expects preliminary, unaudited revenue for Q4 to be ~$698M, an increase of 23% Y/Y (consensus of $696.01M).U.S

SAN DIEGO--(BUSINESS WIRE)--Dexcom to Present at 40th Annual J.P. Morgan Healthcare Conference

These companies have already handsomely rewarded shareholders, but it's not over yet.

Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.

DexCom is one of the leaders in the diabetes care space with their continuous glucose monitoring device. Advanced technology and convenience of use have propelled their revenue growth upward over the

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Halbert Hargrove Global Advisors LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to its most recent filing with the SEC. The firm bought 385 shares of the medical device companys stock, valued at approximately $211,000. Several other institutional investors and hedge funds have also recently modified their holdings of []

Trust Asset Management LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 7.4% in the 3rd quarter, Holdings Channel reports. The fund owned 919 shares of the medical device companys stock after buying an additional 63 shares during the quarter. Trust Asset Management LLCs holdings in DexCom were worth $503,000 as of its most recent []

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 3,000 shares of DexCom stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $535.97, for a total transaction of $1,607,910.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Shares []

Related Stocks: MSI , DXCM , BRKR , A , BURL , WEN , JCI , HUBS , LYV , PLTR , ALK , MCB , MU , MRNA , NXST , FCX , RNG , VMEO , TFX , AKAM , CCK , BAH , ALGN , HEI ,